^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Fibrosarcoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/30/2020
    Excerpt:
    Pembrolizumab (for myxofibrosarcoma, undifferentiated pleomorphic sarcoma [UPS], cutaneous angiosarcoma and undifferentiated sarcomas)...